Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4

de, Oliveira Ferreira Anderson; Polonini, Hudson; Loures, da Silva Sharlene; Buzinari, Aglio Natália Cristina; Abreu, Jordana; Fernandes, Brandão Marcos Antônio

Abstract

Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4

Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio

Issue: Jul/Aug 2017 - Volume 21, Number 4

View All Articles in Issue

Page(s): 339-346

Download in electronic PDF format for $75

Abstract

The objective of this study was to evaluate the stability of 7 commonly used active pharmaceutical ingredients compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend SF PH4): acetazolamide 25.0 mg/mL, baclofen 10.0 mg/mL, dipyridamole 10.0 mg/mL, mebeverine hydrochloride 10.0 mg/mL, propylthiouracil 5.0 mg/mL, quinidine sulfate 10.0 mg/mL, and topiramate 5.0 mg/mL. All suspensions were stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by measuring the percentage recovery at varying time points throughout a 90-day period. Active pharmaceutical ingredient quantification was performed by ultraviolet (UV) high-performance liquid chromatography, via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredient + vehicle) was at least 90 days for all suspensions with regards to both temperatures. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2017 Pg. 339-346	Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
May/Jun 2020 Pg. 224	Baclofen 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 130	Acetazolamide 25 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Nov/Dec 2010 Pg. 512	Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 136	Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2017 Pg. 234	Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base Author(s): Allen Loyd V Jr
Mar/Apr 2024 Pg. 136	Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base Author(s): Allen Loyd V Jr
May/Jun 2012 Pg. 238	Acetazolamide 100-mg/mL Injection Author(s): Allen Loyd V Jr
May/Jun 2019 Pg. 234	Mebeverine Hydrochloride 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 412	Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2024 Pg. 135	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Sep/Oct 2019 Pg. 408	Dipyridamole 10 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
May/Jun 2016 Pg. 231	Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 135	Propylthiouracil 5 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 138	Topiramate 5 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 156-162	Physicochemical Stability of Ternary Mixtures of Sufentanil, Baclofen, and Ropivacaine in Polypropylene Syringes for Intrathecal Analgesia Author(s): Sorrieul Jérémy, Robert Julien, Chapel Fanny, Gossye Thomas, Devys Catherine
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Nov/Dec 2018 Pg. 493	Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr